Clinuvel Pharmaceuticals’ (ASX:CUV, ADR:CLVLY) Singaporean subsidiary Vallaurix Pte Ltd has successfully completed initial in-vitro development of the VLRX001 therapy for depigmentation disorder vitiligo.
VLRX001, a melanocortin analogue is an addition to Clinuvel’s product pipeline alongside CUV9900 and SCENESSE®, which was recently granted marketing authorisation by the European Commission for the rare disease erythropoietic protoporphyria.
Formulation work will focus on the development of VLRX001 for topical self-administration by patients.
The transdermal product will initially be evaluated as adjuvant maintenance therapy for vitiligo.
Patent applications on VLRX001 have been filed in the commercially relevant jurisdictions.
Clinuvel will hold all rights to the final product and indications through Vallaurix.
Melanocortins have long been acknowledged to have a ubiquitous application in medicine.
A renaissance in the demand for novel melanocortin molecules has been seen in clinical research, with more than 400 peer reviewed publications on the use of melanocortins over the past 24 months.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.